Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.25) earnings per share for the quarter, Zacks reports. The company had revenue of $8.09 million for the quarter. Sunshine Biopharma had a negative return on equity of 26.96% and a negative net margin of 18.45%.
Sunshine Biopharma Stock Performance
SBFM traded down $0.13 during trading on Friday, hitting $0.34. The stock had a trading volume of 429,814 shares, compared to its average volume of 58,939. The stock has a 50 day simple moving average of $1.03 and a two-hundred day simple moving average of $1.25. Sunshine Biopharma has a twelve month low of $0.36 and a twelve month high of $2.43. The company has a market capitalization of $1.71 million, a PE ratio of -0.27 and a beta of 1.37.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Sunshine Biopharma in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sunshine Biopharma has an average rating of “Hold” and a consensus price target of $7.00.
Institutional Trading of Sunshine Biopharma
Institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new position in Sunshine Biopharma during the 3rd quarter worth $32,000. Virtu Financial LLC acquired a new stake in Sunshine Biopharma in the fourth quarter worth about $29,000. Finally, Citadel Advisors LLC boosted its holdings in Sunshine Biopharma by 23.1% in the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after acquiring an additional 14,656 shares in the last quarter. Institutional investors and hedge funds own 41.98% of the company’s stock.
Sunshine Biopharma Company Profile
Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.
Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.
Featured Stories
- Five stocks we like better than Sunshine Biopharma
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
